Definitive Additional Materials

Safe Harbor Statement

This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities

Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are

statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and

expectations of InfuSystem’s management, are subject to risks and uncertainties, which could cause actual

results to differ from the forward-looking statements. The following factors, among others, could cause actual

results to differ from those set forth in the forward-looking statements: dependence on our Medicare Supplier

Number;

changes

third

party

reimbursement

rates;

availability

chemotherapy

drugs

our

infusion

pump

systems; physicians’

use of infusion pump therapy over oral medications; our growth strategy, including entry

into new fields of infusion-based therapy and potential acquisitions and strategic alliances; the current global

financial crisis; industry competition; dependence upon our suppliers; and general economic conditions, as

well as other relevant risks detailed in InfuSystem’s filings with the SEC. The information set forth herein

should be read in light of such risks. InfuSystem does not assume any obligation to update information

contained in this presentation.

Definitive Proxy Statement

In connection with the solicitation of agent designation revocations, InfuSystem Holdings, Inc. has filed a

definitive

proxy

statement

with

the

Securities

and

Exchange

Commission

(the

“SEC”).

STOCKHOLDERS

ARE

URGED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS WHEN THEY BECOME

AVAILABLE

BECAUSE

THEY

CONTAIN

IMPORTANT

INFORMATION.

InfuSystem

and

its

directors

and

executive

officers

may

deemed

participants

the

solicitation

agent

designation

revocations.

Stockholders

may obtain additional information regarding such participants and their interests from the definitive proxy

statement

and

from

InfuSystem's

periodic

reports

filed

with

the

SEC.

The

periodic

reports

and

definitive

proxy

statement are available, and other relevant documents will be available, at no charge at the web site of the

SEC. at

www.sec.gov.

Investment Highlights

Leading provider of infusion pumps and related services

Listed on NYSE Amex

Large, growing and highly fragmented market

Multiple growth opportunities

Meaningful

cross-selling

opportunity

from

large

volume

pump

and

biomedical

repair

divisions

Strategic acquisitions of complementary infusion products and services

Favorable reimbursement position

~200 million lives covered

>200 managed care contracts

Targeting overall growth of 15% to 20% (organic w/acquisitions)

17 consecutive quarters of year-over-year revenue growth

Increased

revenues

54%

from

the

months

ended

Dec.

31,

2008

the

months

ended

Dec.

31,

2011

EBITDA margin of approximately 25%+ for the trailing twelve quarters

Strong operating cash flow

Integrated Approach to Infusion

The combined businesses provide a full-service infusion

solution

Third party reimbursement and direct sales

Ambulatory and non-ambulatory pumps

Repair and service

Same point of sale within the oncology office

Core ambulatory pump business continues to see

compelling growth opportunities

Large volume pump division provides significant growth

opportunities in our existing and new markets

InfuSystem is a full-service infusion provider

$1,378

$4,638

$500

$1,000

$1,500

$2,000

$2,500

$3,000

$3,500

$4,000

$4,500

$5,000

2000

2005

2010

2015

2020

Increasing Demand for Health Care Services

National Health Expenditures

In 2009, the U.S. spent $2.5 trillion on

healthcare, or 18% of total GDP

Growth in U.S. national health expenditures has

significantly outpaced the overall economy

Major drivers behind this increase include:

introduction of medical technology, an aging

population, and change in lifestyle

U.S. national health expenditures are expected

to increase to $4.6 trillion by 2020, a 6.3%

CAGR since 2000

($ in billions)

Source: Centers for Medicare & Medicaid Services

Strong Growth in Home Health Spending

The Home Health sector represented an

estimated $68.3 billion of revenue in 2009

Home Health is the lowest-cost clinical setting

for patients, especially those with a chronic

illness or following an inpatient stay

Favorable industry drivers such as an aging

population, cost effectiveness and patient

preference for home care will continue to drive

the industry’s growth

U.S. Home Health spending is expected to

increase to $136 billion by 2020, a 7.4% CAGR

since 2000

$32

$136

$20

$40

$60

$80

$100

$120

$140

$160

2000

2005

2010

2015

2020

Home Health Expenditures

($ in billions)

Source: Centers for Medicare & Medicaid Services

Growing Demand for Infusion Therapy

Colorectal cancer (CRC) is one of the most prevalent forms of cancer in the United

States

The standard of care for the treatment of CRC relies upon continuous

chemotherapy infusions delivered via electronic ambulatory infusion pumps

Clinical evidence demonstrates superior outcomes of continuous chemotherapy

infusions

Payors recognize the positive outcomes and it is reflected in favorable

reimbursement for clinical services related to the delivery of this care

Since 2000, the approval of a number of chemotherapy protocols tied to infusion

have resulted in significantly improved overall survival rates for CRC patients

Source: Centers for Disease Control and Prevention

Increasing Outsourcing of Non-Core Activities

Hospitals are increasingly outsourcing non-core activities to reduce costs,

improve inefficiencies and focus on core high value acute care

competencies

Renting of medical equipment provides healthcare providers with greater

financial and operating flexibility

Reduces

capital expenditures in difficult economic environments

Increases

equipment

utilization

rates

allowing

for

short

term

equipment

investments

Limits equipment obsolesce risk

Helps to manage physician preferences

Eliminates maintenance staffing requirements

Ambulatory Oncology Infusion Overview

Leading provider of ambulatory infusion pumps for

oncologists and their patients with significant market share

Pumps are primarily used for the continuous infusion of

chemotherapy drugs to treat colorectal cancer

Provide a complete solution to doctors & patients

Pumps and related disposable supplies

Billing and collections directly from payors

Maintains, cleans & services equipment

Operates 24/7 oncology certified nurse-staffed patient support hotline

Strong, leverageable relationships with 1,400+ oncology clinics

Ambulatory Oncology Infusion Service Model

New Patient prescribed

CI pump by physician

Step 1

CI pump programmed,

drug loaded and therapy

initiated in physician’s office

Step 2

Patient wears pump for

infusion regimen

(22-46 hours/treatment)

Step 3

Documentation collected

from physician’s office and

claims submitted to payors

by InfuSystem

Step 4*

Pump returned to

InfuSystem for cleaning

and maintenance

Step 5

* Steps 1-4 are repeated for a given patient over their 4-6 month treatment cycle

Consignment Service Line

Target Market Penetration

InfuSystem measures its market share not in terms of

the number of practices, but in the pool of

addressable patients

The Company estimates the number of patients with a

particular diagnosis code in its 'book of business' to

the total number of patients diagnosed with those

cancer types each year

The Company estimates how the other sectors divides

what's left based on its own intimate knowledge of the

market

The breakdown of the Company’s current market

share shows that despite being the predominant

national player in continuous infusion, there is ample

room for organic growth

INFU

20%

Other

DME

10%

Own/

Rent

20%

Home

Infusion

Provider

40%

Other

10%

20%

40%

60%

80%

100%

Market Share

•Strengthens relationship with patient

•Extensive managed care contracts

•Professional service fee

•Less capital intensive

•Billing provided

Value to Patients

•Continuity of care

•Reduced side effects

•Comfort and convenience

Value to Payors

•Lower cost

•State of the art patient care

•Improved patient outcomes

Compelling Ambulatory Value Proposition

Win-win-win proposition: patients, payors and providers all benefit

Value to Physicians

Large Volume Pump Division

Sells, rents, services and repairs new and pre-owned infusion

pumps and other medical equipment

Convenience and flexibility of rentals & leases that don’t require

capital outlays but eliminate hassle of maintenance/service

Leading provider to alternate site healthcare facilities and

hospitals in the United States and Canada

Minimal reimbursement revenue; transacts directly with

healthcare providers

Sells a variety of primary and secondary tubing, cassettes,

catheters and other disposable items that are utilized with

infusion pumps

World class biomedical repair for pumps, defibrillators, SCD's

and most other general medical equipment

Market Opportunity

Ambulatory infusion

oncology

Significant market share

Competition: home infusion

providers, physician owned

pumps, and independent

providers

Source: Company estimates

Ambulatory Oncology

Infusion

Oncology Infusion

Large volume pump

division broadens

market to overall

Oncology infusion

Pump sales and rentals

Portfolio of over 70

different pumps

Consumables

Same point of sale within

Oncology clinic

Non-oncology applications

Pain, Nutrition, Hydration

Non-oncology locations

Hospitals

Alternate site facilities

Long-term care

Research facilities

Biomedical repair & service

Routine maintenance

Service repair

Needed in all infusion settings

Potential

party

reimbursement model

Infusion

Growth Opportunity: Organic

New Clinic Opportunity

Convert clinics to InfuSystem

~5,000 new clinic opportunities

Cross-selling

Offer biomedical repair & service nationwide to current InfuSystem customers

Rent/sell a portfolio of pumps –

Large volume pump division offers over 70

different models of infusion pumps to our clients

Expand large volume pump offering nationwide

Build relationships with First Biomedical Inc. oncology clinics that were not

InfuSystem customers

Explore 3

party billing opportunities outside of oncology

Targeting 5% to 8% organic revenue growth

InfuSystem Has the Right Plan in Place to Deliver

Long-Term Value

Company’s core vision is to become a significant leader in the

infusion and pre-owned medical equipment markets

Large, growing and highly fragmented market

Multiple growth opportunities to increase revenues

Meaningful

cross-selling

opportunity

from

large

volume

pump

and

biomedical

repair

divisions

Strategic acquisitions of complementary infusion products and services

Targeting overall growth of 15% to 20% (organic w/acquisitions)

while maintaining attractive EBITDA margins

17 consecutive quarters of year-over-year revenue growth

Increased

revenues

54%

from

the

months

ended

Dec.

31,

2008

the

months

ended

Dec.

31, 2011

Strong operating cash flow

InfuSystem is well positioned for growth through multiple strategic

and organic opportunities

New Leadership Team is Successfully

Executing on the Strategic Plan

The Company’s key executives have

only been in their positions for short

periods of time

Sean McDevitt has been Chief

Executive Officer since September

2009

James Froisland has been Chief

Financial Officer since only December

2010

David Haar has been Head of Sales

since only November 2010

There is a clear action plan in place to

continue to capitalize on significant

growth opportunities available

Growth YOY

10%

21%

2009

2010

2011

$54.6

16%

Revenue

$39.0

$47.2

Balance Sheet Highlights

(in thousands)

12/31/2010

9/30/2011

ASSETS

Cash and Cash Equivalents

5,014

433

Total Current Assets

15,289

12,556

Total Assets

130,364

79,492

LIABILITIES

Total Current Liabilities (excl. derivative liabilities)

12,198

10,471

Long-term Debt (incl. current portion)

32,197

30,248

Total Liabilities

45,221

38,771

TOTAL STOCKHOLDERS' EQUITY

85,143

40,721

CAPITAL STRUCTURE

9/30/2011

Common Shares Outstanding (as of Nov. 8, 2011)

21.2 million

Term Debt (both long and short term)

$25.1 million

Revolver

$5.0 million (unused balance of $4.9 million)

A Special Meeting is Unnecessary & Costly

The Board does not believe that a special meeting serves the interests of

InfuSystem stockholders

The Board values input from stockholders and is always open to

stockholder input regarding the composition of the Board

The entire Board will be up for election at the 2012 annual meeting of

stockholders to be held in the spring

The special meeting has been demanded by a group of dissident

stockholders who have not articulated any plans for InfuSystem

The Kleinheinz Dissident Group has chosen to engage in a disruptive proxy

contest that will inflict significant costs on stockholders

•

Six of seven Board members are independent

–

David Dreyer

–

Timothy Kopra

–

Pat LaVecchia –

Vice Chairman

–

Jean-Pierre Millon

–

John Voris

–

Wayne Yetter

InfuSystem’s Board is comprised of seasoned executives,

all of whom are actively engaged in creating value for all stockholders

InfuSystem has a Highly-Qualified and

Independent Board

•

Sean McDevitt–Chief Executive Officer and Chairman

•

All directors have a deep understanding of InfuSystem’s business,

significant healthcare industry knowledge and experience as public

company directors

Strong Corporate Governance Profile

Strong, experienced, independent Board

Board is elected annually

Wholly independent Audit, Compensation and Governance &

Nominating committees

Board members own approximately 17.3% of the Company’s

outstanding shares, aligning their interests with those of

stockholders

InfuSystem’s Board is committed to ensuring that InfuSystem has the right plan

and governance structure in place to deliver the most value to stockholders

The Board Values the Input of Our Stockholders

While the Board believes that the Company has the correct

strategic plan and leadership in place, it remains open to all ideas

designed to enhance stockholder value

The Board and management team, with the assistance of

independent financial advisors, regularly undertake a thorough

review of strategic alternatives

The Board remains open to all ideas designed to enhance

stockholder value, but the Kleinheinz Dissident Group has refused

to share with the Company any ideas for enhancing stockholder

value despite several requests

The Kleinheinz Dissident Group owns only 11.4% of the Company, yet is

asking for full control of the company without paying a customary control

premium

date,

the

Kleinheinz

Dissident

Group

has

failed

articulate

any

plan

proposal to create enhanced value for InfuSystem stockholders

The Kleinheinz Dissident Group’s Solicitation Statement also provides no

information as to what actions the group might undertake to improve

stockholder value if it were to gain control of the Board

Rather than engage with the Company constructively, the Kleinheinz

Dissident Group has made baseless allegations that the Board is “actively

impeding improvements”

without offering any examples of such behavior

The Kleinheinz Dissident Group has Not

Articulated a New Strategy for the Company

If the Kleinheinz Dissident Group were to take control of the Board, there

would be several immediate adverse consequences to InfuSystem:

An event of default would occur under the Company’s Credit Agreement and would give

lenders the right to declare the outstanding principal and accrued interest ($25.1 as of

September 30, 2011) due and payable

The Kleinheinz Dissident Group has categorically stated it believes the lenders would be

unlikely to exercise this right, but admits that this assertion is not informed by any discussions

with the Company’s lenders

InfuSystem’s business depends upon its management’s deep knowledge of the industry,

relationships with third-party payors and the relationships between its sales forces and

its customers, and the Board believes InfuSystem may have difficulty retaining key

employees

The Kleinheinz Dissident Group has not disclosed any plans for addressing

these adverse consequences

The Kleinheinz Dissident Group has Not Addressed

Adverse Consequences of Replacing Entire Board

The Kleinheinz Dissident Group Nominees –

Not Right for InfuSystem

The Company believes that the Kleinheinz Dissident Group’s nominees

would fail to enhance the composition of the Board

Five of the seven nominees have no meaningful experience in the healthcare

industry

In our view, electing the Kleinheinz Dissident Group nominees could:

Interrupt the ongoing implementation of InfuSystem’s

strategic plan;

Disrupt the ongoing strategic alternatives review process;

Reduce the level of relevant experience on the Board; and

Negatively impact stockholder value

Electing the dissident’s nominees could interrupt the ongoing implementation of

the strategic plan and may negatively impact stockholder value

Do not designate the Kleinheinz Dissident Group as an agent for your

shares –

do not sign their white agent designation card

The Kleinheinz Dissident Group’s nominees have neither the qualifications

nor the experience to assist the Board in creating stockholder value

InfuSystem’s Board and management have:

–

Taken extensive measures to position InfuSystem for continued success as

well as to enhance stockholder value

–

Developed a strategic plan that puts InfuSystem on a trajectory of significant

revenue growth in revenue which is already delivering results

Support your Board’s efforts to drive value for ALL stockholders –

Sign the BLUE Revocation Card today

Protect Your Investment: Do Not Allow the Kleinheinz

Dissident Group to Take Control of the Board

GAAP Reconciliation -

Annual

(in millions)

2008

2009

2010

Net (loss) income

10.0

0.8

(1.9)

Adjustments:

Interest expense

3.8

3.5

3.4

Income tax (benefit) expense

0.9

1.0

(1.4)

Depreciation

3.9

4.1

5.4

Amortization

1.8

2.2

EBITDA

20.4

11.2

7.7

Adjustments:

Asset impairment charges

(Gain) loss on derivatives

(9.8)

0.1

(0.2)

Stock based compensation

1.5

0.7

5.9

Sales and other incentives

0.2

Acquisition related expenses

1.0

Severance

0.9

0.5

(Gain) on debt extinguishment

(1.1)

Adjusted EBITDA

12.1

12.9

14.0

Adjusted EBITDA Margin

34%

33%

30%

GAAP Reconciliation -

Quarterly

(in millions)

4Q10

1Q11

2Q11

3Q11

Net (loss) income

(2.1)

(0.2)

(27.6)

(16.6)

Adjustments:

Interest expense

0.6

0.5

0.6

0.5

Income tax (benefit) expense

(1.3)

(0.1)

(15.8)

(6.5)

Depreciation

1.5

1.6

1.7

Amortization

0.6

0.7

EBITDA

(0.7)

2.4

(40.5)

(20.2)

Adjustments:

Asset impairment charges

43.7

23.4

(Gain) loss on derivatives

(0.4)

(0.1)

Stock based compensation

4.1

0.3

0.2

0.4

Sales and other incentives

0.2

0.4

0.3

Acquisition related expenses

0.2

0.1

0.4

Severance

0.5

0.1

(Gain) on debt extinguishment

Adjusted EBITDA

3.7

3.3

3.8

4.0

Adjusted EBITDA Margin

28%

25%

29%

27%

InfuSystem Directors

Sean McDevitt (Chief Executive Officer and Chairman of the Board)

Sean McDevitt has served as the Company’s Chief Executive Officer since September 2009 and Chairman of the

Board of Directors since August 2005. Previously, Mr. McDevitt was a Managing Director of FTN Midwest

Securities Corp. from September 2004 to January 2007. In 1999, Mr. McDevitt co-founded Alterity Partners, a

boutique investment bank which provided capital markets and merger and acquisition advisory services to

high growth companies. Alterity Partners was acquired by FTN Midwest Securities Corp. in September 2004.

Mr. McDevitt was formerly a senior investment banker at Goldman Sachs & Company from 1995 through 1999

where

led

deal

teams

variety

technology

and

healthcare/biopharmaceutical

transactions,

including

mergers and acquisitions, divestitures and initial public offerings. Prior to Goldman Sachs & Company, Mr.

McDevitt worked in sales and marketing at Pfizer Inc. from 1991 until 1994. He was a Captain in the U.S. Army

Rangers and was decorated for combat in the Panama invasion. He is a member of the Council on Foreign

Relations. Mr. McDevitt received his B.S. in Computer Science and Electrical Engineering from the U.S. Military

Academy at West Point and an M.B.A. from Harvard Business School. Mr. McDevitt brings to the Company and

the Board of Directors extensive experience as an investment banker, especially dealing with mergers,

acquisitions and other transactions in the healthcare industry.

InfuSystem Directors

David Dreyer

David Dreyer has been a member of the Company’s Board of Directors since April 2008. Mr. Dreyer has served

as Chief Financial Officer and Secretary of Patient Safety Technologies (OTCBB: PSTX), since October 2010.

Previously Mr. Dreyer was Chief Financial Officer of Alphastaff Group, Inc., a human resource outsourcing

company,

from

August

2009

September

2010.

Mr.

Dreyer

served

Chief

Financial

Officer

and

Chief

Accounting Officer of AMN Healthcare Services, Inc. (NYSE: AHS) from September 2004 to August 2009, and

Treasurer from 2006 to August 2009. During Mr. Dreyer’s tenure, AMN grew to become the leader in

healthcare staffing for physicians, travel nurses, and allied travel, doubling its revenue to $1.2 billion in 4 years.

From 1997 through 2004, Mr. Dreyer served as Chief Financial Officer and Chief Accounting Officer of Sicor,

Inc., a manufacturer of complex pharmaceuticals with operations in the United States, Italy, Mexico, Lithuania,

China

and

Switzerland,

which

was

acquired

Teva

Pharmaceutical

Limited.

Prior

joining

Sicor,

Mr.

Dreyer

served in related senior financial management positions within the pharmaceutical industry, working for Elan

Corporation plc, Athena Neurosciences and Syntex. Mr. Dreyer is a Certified Public Accountant in California.

Mr. Dreyer brings to the Company and the Board of Directors financial expertise from his experience serving as

a Chief Financial Officer of Sicor, Inc., AMN Healthcare Services, Inc. and Alphastaff Group, Inc.

InfuSystem Directors

Timothy Kopra

Timothy Kopra has been a member of the Company’s Board of Directors since April 8, 2010. Mr. Kopra began

his military service in 1985 and has held a variety of leadership and technical positions as a U.S. Army officer

and aviator. After assignments within the U.S. and Germany and deployment to Operations Desert Shield and

Desert Storm, Mr. Kopra completed the U.S. Navy Test Pilot School and was designated as an experimental test

pilot in 1996. He then served as the developmental test director for the Comanche helicopter program. In July

2000, Mr. Kopra was selected as an astronaut and completed two years of Space Shuttle, Space Station, and T-

38 flight training. Mr. Kopra then served in the Astronaut Office, where his primary focus involved testing crew

interfaces

for

International

Space

Station

(ISS)

unpressurized

modules

well

the

implementation

support

computers

and

operational

Local

Area

Network

ISS.

Mr.

Kopra

completed

his

first

space

flight

2009, logging two months in space and one spacewalk. Mr. Kopra continues to be an employee of the National

Aeronautics and Space Administration (NASA). Mr. Kopra received a Bachelor of Science from the United States

Military

Academy

West

Point,

Master

Science

Aerospace

Engineering

from

the

Georgia

Institute

Technology,

and

Master

Strategic

Studies

from

the

U.S.

Army

War

College.

Mr.

Kopra

also

expects

receive a Masters of Business Administration from Columbia University and the London Business School in

December

2012.

Mr.

Kopra’s

science

and

technology

experience

and

backgrounds

are

valuable

the

Company.

InfuSystem Directors

Pat LaVecchia (Vice Chairman of the Board)

Pat LaVecchia has been a member of the Company’s Board of Directors since September 2005 and has served as Vice

Chairman since September 2009. Mr. LaVecchia served as the Company’s secretary from September 2005 to November

2007. Mr. LaVecchia has been a founding principal and Managing Partner of LaVecchia Capital LLC, a merchant banking

and investment firm, since 2007 and has over 20 years of experience on Wall Street. Mr. LaVecchia has built and run

several major Wall Street groups and has extensive expertise in capital markets, including initial public offerings,

secondary offerings, raising capital for private companies and PIPEs as well as playing the leading role in numerous

mergers, acquisitions, private placements and high yield transactions. Prior to forming LaVecchia Capital, Mr. LaVecchia

ran several groups at major Wall Street firms including: Managing Director and Head of the Private Equity Placement

Group at Bear, Stearns & Company (1994 to 1997); Group Head of Global Private Corporate Equity Placements at

Credit

Suisse

First

Boston

(1997

2000);

Managing

Director

and

Group

Head

the

Private

Finance

and

Sponsors

Group at Legg Mason Wood Walker, Inc (2001 to 2003); co-founder and Managing Partner of Viant Group (2003-2005)

and

Managing

Director

and

Head

Capital

Markets

FTN

Midwest

Securities

Corp.

(2005

2007).

was

also

Hawk Holdings, a strategic venture capital firm from 2000 until 2001. Mr. LaVecchia received his B.A., magna cum

laude

(and

was

elected

Phi

Beta

Kappa),

from

Clark

University

and

M.B.A.

from

The

Wharton

School

the

University of Pennsylvania with a major in Finance and a concentration in Strategic Planning. Mr. LaVecchia also

currently

serves

co-chairman

Premiere

Opportunities

Group,

Inc.

(PPBL,

OTC)

and

board

member

Next1

Interactive, Inc. (NXOI, OTC), both of which are development stage companies. Mr. LaVecchia also sits on several

advisory boards and non-profit boards and is a member of the NYSE AMEX Listed Company Council. Mr. LaVecchia

brings to the Company and the Board of Directors a strong background in capital markets from his experience in

investment banking.

InfuSystem Directors

Jean-Pierre Millon

Jean-Pierre Millon has served as a member of the Company’s Board of Directors since September 2005. Mr.

Millon is a co-founder of BLS, LLC, a consulting and investing entity based in Indianapolis and established in

2002. Mr. Millon served as a consultant to AdvancePCS, successor entity to PCS Health Systems, from October

2000 to June 2002. Until September 2000, Mr. Millon was President and Chief Executive Officer of PCS Health

Systems, one of the country’s largest pharmacy benefit managers. Prior to joining PCS in 1995, Mr. Millon was

executive

with

Eli

Lilly

and

Co.,

PCS’

former

parent

company.

His

career

with

Lilly,

started

1976,

spanned

two decades and was highlighted by leadership positions in the United States, the Orient, Europe and the

Caribbean Basin. Most recently, Mr. Millon served as President and General Manager of Lilly Japan, K.K. and

Vice President of the Lilly pharmaceutical division in Kobe, Japan from 1992 until 1995. Mr. Millon was an

advisory board member with Care Capital LLC, a healthcare venture fund from 2001 through 2003. Mr. Millon

also serves on the Board of Directors of CVS/Caremark Corporation (NYSE: CVS), HSI, Inc. and Tummy Inc. Mr.

Millon’s experience serving on various boards of directors and as an officer of other companies in the

healthcare industry is valuable to the Company.

InfuSystem Directors

John Voris

John Voris has been a member of the Company’s Board of Directors since September 2005. Mr. Voris served as

the Company’s Chief Executive Officer from September 2005 until October 2007. From August 2004 to July

2005, Mr. Voris was Chairman of Epocrates, Inc., a software company providing clinical information to

healthcare

professionals

the

point

care.

Mr.

Voris

retired

from

his

position

Epocrates

July

2005

and

did not accept another position until becoming the Company’s Chief Executive Officer and a member of the

Board

Directors

September

2005.

was

President

and

Chief

Executive

Officer

Epocrates

from

June

2000 until July 2004. Prior to Epocrates, Mr. Voris was Executive Vice President of PCS Health Systems from

1995 until 2000. During his tenure at PCS Health Systems, PCS Health Systems was a subsidiary of Eli Lilly from

1994 until 1999 and then of Rite Aid Pharmacies from 1999 until 2000. While at PCS, Mr. Voris had

responsibility for all call centers, mail order pharmacies, sales and marketing of PBM services, product

development and industry relations. Prior to PCS, Mr. Voris was with Eli Lilly from 1973 until 1995. Mr. Voris

was Executive Director of the Infectious Disease Business Unit from 1993 until 1995, where he was responsible

for world wide sales and marketing of a large portfolio of existing and development-stage anti-infectives. From

1988 until 1992, Mr. Voris was based in London as Director of Marketing for Europe, Middle East and Africa,

where

had

responsibility

for

sales,

marketing

and

product

development

for

the

entire

portfolio

Lilly

pharmaceutical products. Prior to these positions, he held a variety of positions in sales, marketing, market

research

and

business

development.

Mr.

Voris

received

his

M.B.A.

and

B.S.

from

the

Kelley

School

Business,

Indiana University. Mr. Voris currently serves as Chairman of the Board of Directors of Regenesis Biomedical.

Mr. Voris’

experience serving on various boards of directors and as an officer of other companies in the

healthcare industry is valuable to the Company.

InfuSystem Directors

Wayne Yetter

Wayne Yetter has served a member of the Company’s Board of Directors since September 2005. He served as

Chief Executive Officer of Verispan, LLC, a healthcare information company founded by Quintiles Transnational

Corp. and McKesson Corp, from September 2005 to August 2008. From November 2004 through September

2005, Mr. Yetter served as President and Chief Executive Officer of Odyssey Pharmaceuticals, Inc. to assist

Odyssey’s parent, PLIVA d.d., implement its strategy to exit the proprietary pharmaceutical business. Mr. Yetter

has built and led a variety of multi-million dollar businesses and pharmaceutical operations for some of the

largest companies in the world. After serving in Vietnam, Mr. Yetter began his career in the pharmaceuticals

industry in 1970 as a sales representative for Pfizer. From Pfizer, he joined Merck & Co in 1977, where he led the

Marketing Operations Group and then became President of the Asia Pacific region before starting the new

company, Astra Merck, in 1991 as President and Chief Executive Officer. Under his leadership, Astra Merck’s

product, Prilosec, grew to be the #1 pharmaceutical product in the United States at the time. Mr. Yetter then

joined Novartis Pharmaceuticals in 1997, where he was President and Chief Executive Officer of the United States

pharmaceutical business. In 1999, he joined IMS and later led its spinout company, Synavant, where he was

Chairman and Chief Executive Officer for three years before Synavant merged with Dendrite International in

2003. He also served as an advisor to Alterity Partners from 2003 until 2004. Mr. Yetter was formerly Chairman

of the Board for Transkaryotic Therapies Inc., which was acquired by Shire Pharmaceuticals. Mr. Yetter currently

serves on the Board of Directors of EpiCept Corporation (OTCOX: EPCT), Strategic Diagnostics Inc. (NASDAQ:

SDIX) and is Chairman of the Board of NuPathe, Inc. (NASDAQ: PATH). Mr. Yetter’s experience serving on various

boards of directors and as an officer of other companies in the healthcare industry is valuable to the Company.


¨	Preliminary Proxy Statement

¨	Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨	Definitive Proxy Statement

x	Definitive Additional Materials

¨	Soliciting Material Pursuant to § 240.14a-12

InfuSystem Holdings, Inc.
(Name of Registrant as Specified In Its Charter)


(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x	No fee required.

¨	Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

	(1)	Title of each class of securities to which transaction applies:

	(2)	Aggregate number of securities to which transaction applies:

	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	(4)	Proposed maximum aggregate value of transaction:

	(5)	Total fee paid:




¨	Fee paid previously with preliminary materials.

¨	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	(1)	Amount Previously Paid:

	(2)	Form, Schedule or Registration Statement No.:

	(3)	Filing Party:

	(4)	Date Filed: